Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology-Reference-Cited by-同舟云学术

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

Published:2016-09-09 Issue:9 Volume:11 Page:e0161779
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Selby Mark J.,Engelhardt John J.,Johnston Robert J.,Lu Li-Sheng,Han Minhua,Thudium Kent,Yao Dapeng,Quigley Michael,Valle Jose,Wang Changyu,Chen Bing,Cardarelli Pina M.,Blanset Diann,Korman Alan J.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference57 articles.

1. Molecular mechanisms of T cell co-stimulation and co-inhibition;L Chen;Nat Rev Immunol,2013

2. The blockade of immune checkpoints in cancer immunotherapy;DM Pardoll;Nat Rev Cancer,2012

3. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma;JD Wolchok;Ann N Y Acad Sci,2013

4. Nivolumab: targeting PD-1 to bolster antitumor immunity;JR Brahmer;Future Oncol,2015

5. Evolving synergistic combinations of targeted immunotherapies to combat cancer;I Melero;Nat Rev Cancer,2015

Cited by 189 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel anti-FGFR1 monoclonal antibody OM-RCA-01 exhibits potent antitumor activity and enhances the efficacy of immune checkpoint inhibitors in lung cancer models;Immuno-Oncology and Technology;2024-09

2. Validation of the C-X-C chemokine receptor 3 (CXCR3) as a target for PET imaging of T cell activation;EJNMMI Research;2024-08-28

3. OMIP‐105: A 30‐color full‐spectrum flow cytometry panel to characterize the immune cell landscape in spleen and tumor within a syngeneic MC‐38 murine colon carcinoma model;Cytometry Part A;2024-08-06

4. Mapping the genetic landscape establishing a tumor immune microenvironment favorable for anti-PD-1 response in mice and humans;2024-07-16

5. Immune‐related adverse events of antibody‐based biological medicines in cancer therapy;Journal of Cellular and Molecular Medicine;2024-07